D-cycloserine Augmented CBT for Panic Disorder

The Effect of a Single-dose of D-cycloserine on the Basic Effects of Cognitive-behaviour Therapy for Panic Disorder - a Randomized Placebo-controlled Trial

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01680107

Enrollment

Registered

2012-09-06

Start date

2012-10-31

Completion date

2018-04-30

Last updated

2018-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Panic Disorder

Keywords

d-cycloserine, cognitive-behaviour therapy, panic disorder

Brief summary

The purpose of this study is to determine whether d-cycloserine augments the clinical effects of exposure-based cognitive-behaviour therapy for panic disorder.

Interventions

DRUGd-cycloserine

DRUGplacebo

BEHAVIORALcognitive-behaviour therapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* clinical diagnosis of panic disorder * at least moderate agoraphobic avoidance

Exclusion criteria

* psychoactive medication last 6 weeks * exposure-based cognitive-behaviour treatment for panic disorder and agoraphobia during last 3 months * female participant who is pregnant or breast-feeding * lifetime history of psychosis, bipolar disorder, alcohol, medication or drug abuse or dependence; current primary depressive disorder * lifetime history of epilepsy or other significant disease or disorder

Design outcomes

Primary

Measure	Time frame
self-reported and clinician-rated anxiety and depression measures	6 months

Secondary

Measure	Time frame
emotional information processing	1 day

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026